Literature DB >> 25641666

A pharmacokinetic model of oral methylphenidate in the rat and effects on behavior.

Panayotis K Thanos1, Lisa S Robison2, Jessica Steier2, Yu Fen Hwang2, Thomas Cooper3, James M Swanson4, David E Komatsu5, Michael Hadjiargyrou6, Nora D Volkow7.   

Abstract

Most animal studies using methylphenidate (MP) do not administer it the same way it is administered clinically (orally), but rather by injection, resulting in an altered pharmacokinetic profile (quicker and higher peak concentrations). We evaluated several oral-dosing regimens in rats, including dual-dose drinking, to mimic clinical drug delivery. Using an 8-hour-limited-access-drinking-paradigm, MP solutions were delivered at different doses (20, 30, or 60mg/kg/day; as well as dual-dosages of 4 and 10mg/kg/day, 20 and 30mg/kg/day, or 30 and 60mg/kg/day, in which the low dose was administered in the first hour of drinking followed by 7 h of drinking the high dose). Plasma was assayed for MP levels at many time points. Results showed that an 8-hour limited drinking of a dual-dosage 30/60mg/kg MP solution achieved a pharmacokinetic profile similar to clinically administered doses of MP at the high end of the spectrum (peaking at ~30ng/mL), while the 4/10mg/kg MP dual-dosage produced plasma levels in the range produced by typically prescribed clinical doses of MP (peaking at ~8ng/mL). Treatment with the higher dual-dosage (HD: 30/60mg/kg) resulted in hyperactivity, while the lower (LD: 4/10mg/kg) had no effect. Chronic effects of these dual-dosages were assessed throughout three months of treatment and one month of abstinence, beginning in adolescence. MP dose-dependently decreased body weight, which remained attenuated throughout abstinence. MP decreased food intake during early treatment, suggesting that MP may be an appetite suppressant and may also speed metabolism and/or suppress growth. Chronic HD MP resulted in hyperactivity limited during the dark cycle, decreased exploratory behavior, and increased anxiolytic behavior. Findings suggest that these dual-dosage-drinking-paradigms can be used to examine the effects of clinically relevant pharmacokinetic doses of MP and that chronic treatment with such dosages can result in long-lasting developmental and behavioral changes.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Attention deficit hyperactivity disorder; Dopamine transporter; Methylphenidate; Psychostimulant; Ritalin

Mesh:

Substances:

Year:  2015        PMID: 25641666      PMCID: PMC4461871          DOI: 10.1016/j.pbb.2015.01.005

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  68 in total

Review 1.  Incentive-sensitization and addiction.

Authors:  T E Robinson; K C Berridge
Journal:  Addiction       Date:  2001-01       Impact factor: 6.526

2.  Depression of growth in hyperactive children on stimulant drugs.

Authors:  D Safer; R Allen; E Barr
Journal:  N Engl J Med       Date:  1972-08-03       Impact factor: 91.245

3.  Locomotor effects of acute and repeated threshold doses of amphetamine and methylphenidate: relative roles of dopamine and norepinephrine.

Authors:  R Kuczenski; D S Segal
Journal:  J Pharmacol Exp Ther       Date:  2001-03       Impact factor: 4.030

4.  Chronic methylphenidate alters locomotor activity and dopamine transporters differently from cocaine.

Authors:  S Izenwasser; A E Coy; B Ladenheim; R J Loeloff; J L Cadet; D French
Journal:  Eur J Pharmacol       Date:  1999-06-04       Impact factor: 4.432

5.  Repeated methylphenidate treatment in adolescent rats alters gene regulation in the striatum.

Authors:  Cindy L Brandon; Heinz Steiner
Journal:  Eur J Neurosci       Date:  2003-09       Impact factor: 3.386

6.  Pharmacokinetics of methylphenidate in man, rat and monkey.

Authors:  W Wargin; K Patrick; C Kilts; C T Gualtieri; K Ellington; R A Mueller; G Kraemer; G R Breese
Journal:  J Pharmacol Exp Ther       Date:  1983-08       Impact factor: 4.030

7.  Effects of methamphetamine on novelty-seeking behaviour by mice.

Authors:  R Misslin; P Ropartz
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

Review 8.  Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter?

Authors:  John S Markowitz; Kennerly S Patrick
Journal:  J Clin Psychopharmacol       Date:  2008-06       Impact factor: 3.153

9.  Dissociation between spontaneously hypertensive (SHR) and Wistar-Kyoto (WKY) rats in baseline performance and methylphenidate response on measures of attention, impulsivity and hyperactivity in a Visual Stimulus Position Discrimination Task.

Authors:  Panayotis K Thanos; Iliyan Ivanov; John K Robinson; Michael Michaelides; Gene-Jack Wang; James M Swanson; Jeffrey H Newcorn; Nora D Volkow
Journal:  Pharmacol Biochem Behav       Date:  2009-10-08       Impact factor: 3.533

10.  Growth of hyperactive children on maintenance regimen of methylphenidate.

Authors:  J A Mattes; R Gittelman
Journal:  Arch Gen Psychiatry       Date:  1983-03
View more
  17 in total

1.  Comparison of the VTA and LC response to methylphenidate: a concomitant behavioral and neuronal study of adolescent male rats.

Authors:  Tahseen J Karim; Cruz Reyes-Vazquez; Nachum Dafny
Journal:  J Neurophysiol       Date:  2017-06-14       Impact factor: 2.714

2.  Chronic oral methylphenidate treatment increases microglial activation in rats.

Authors:  Emily Carias; John Hamilton; Lisa S Robison; Foteini Delis; Rina Eiden; Teresa Quattrin; Michael Hadjiargyrou; David Komatsu; Panayotis K Thanos
Journal:  J Neural Transm (Vienna)       Date:  2018-09-20       Impact factor: 3.575

3.  Methylphenidate alleviates manganese-induced impulsivity but not distractibility.

Authors:  Stephane A Beaudin; Barbara J Strupp; Walter Uribe; Lauren Ysais; Myla Strawderman; Donald R Smith
Journal:  Neurotoxicol Teratol       Date:  2017-03-28       Impact factor: 3.763

4.  Repeated restraint stress potentiates methylphenidate and modafinil-induced behavioral sensitization in rats.

Authors:  Nausheen Alam; Kulsoom Chaudhary
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-12-18       Impact factor: 3.000

5.  Does methylphenidate use affect sperm parameters in patients undergoing infertility investigation? A retrospective analysis of 9769 semen samples.

Authors:  Hadar Shalev; Yuval Mizrakli; Iris Har-Vardi; Eliahu Levitas; Atif Zeadna; Avi Harlev; Etan Levitas; Gal Ifergane; Eitan Lunenfeld; Victor Novack
Journal:  Arch Gynecol Obstet       Date:  2021-01-12       Impact factor: 2.344

6.  Brief and extended abstinence from chronic oral methylphenidate treatment produces reversible behavioral and physiological effects.

Authors:  Leanna Kalinowski; Carly Connor; Rathini Somanesan; Emily Carias; Kaleigh Richer; Lauren Smith; Connor Martin; Macauley Mackintosh; Daniel Popoola; Michael Hadjiargyrou; David E Komatsu; Panayotis K Thanos
Journal:  Dev Psychobiol       Date:  2019-08-27       Impact factor: 3.038

7.  Chronic oral methylphenidate treatment reversibly increases striatal dopamine transporter and dopamine type 1 receptor binding in rats.

Authors:  Lisa S Robison; Mala Ananth; Michael Hadjiargyrou; David E Komatsu; Panayotis K Thanos
Journal:  J Neural Transm (Vienna)       Date:  2017-01-23       Impact factor: 3.575

8.  Recovery from behavior and developmental effects of chronic oral methylphenidate following an abstinence period.

Authors:  Connor Martin; Dennis Fricke; Abisha Vijayashanthar; Courtney Lowinger; Dimitris Koutsomitis; Daniel Popoola; Michael Hadjiargyrou; David E Komatsu; Panayotis K Thanos
Journal:  Pharmacol Biochem Behav       Date:  2018-07-18       Impact factor: 3.533

9.  Weekday-only chronic oral methylphenidate self-administration in male rats: Reversibility of the behavioral and physiological effects.

Authors:  Emily Carias; Dennis Fricke; Abisha Vijayashanthar; Lauren Smith; Rathini Somanesan; Connor Martin; Leanna Kalinowski; Daniel Popoola; Michael Hadjiargyrou; David E Komatsu; Panayotis K Thanos
Journal:  Behav Brain Res       Date:  2018-08-24       Impact factor: 3.332

10.  Haloperidol attenuates Methylphenidate and Modafinil induced behavioural sensitization and cognitive enhancement.

Authors:  Nausheen Alam; Kulsoom Choudhary
Journal:  Metab Brain Dis       Date:  2018-02-22       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.